Actively Recruiting
Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion
Led by The Cleveland Clinic · Updated on 2026-01-07
850
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Discarded perfusate samples will be collected from donors after circulatory death (DCD) or donors after brain death (DBD) organs during the machine perfusion period prior to transplantation by the study team. FMN will be measured as is standard of care for all machine perfusion liver transplant cases at Cleveland Clinic. Participating centers will be provided with sample collection and shipping instructions to ensure sample preservation in accordance with IATA guidelines. Samples from outside sites will not be stored for future research and will be discarded once analysis is completed. After the collection of the samples from machine perfusion, the transplant procedure will continue according to standard process.
CONDITIONS
Official Title
Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Any donor graft type (donation after brain death or circulatory death)
- Any underlying recipient disease including end stage liver disease or liver tumor
- Acceptable donor risk factors and static cold storage time prior to normothermic machine perfusion as approved by the transplant center
- Patients undergoing primary deceased donor liver transplantation with back-to-base normothermic machine perfusion using OrganOx metra from July 15, 2025 to December 31, 2027 (Cleveland Clinic only)
- Patients who underwent deceased donor liver transplantation with back-to-base normothermic machine perfusion using OrganOx metra from October 22, 2022 to July 14, 2025 (Cleveland Clinic only)
You will not qualify if you...
- Liver grafts not perfused with OrganOx metra
- Pediatric recipients under 18 years old
- Patients listed for super urgent liver transplantation due to acute liver failure
- Patients receiving combined organ transplants (heart+liver, lung+liver, liver+kidney, liver+intestine)
- Patients receiving living donor liver transplant, split or reduced liver transplantation, or domino grafts
- Patients undergoing re-transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
M
Mary Bilancini, MS
CONTACT
E
Erlind Allkushi, BS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here